Immix Biopharma, Inc.
NASDAQ:IMMXBiotechnology
+$0.09 today
- Market cap
- $595.91M
- Beta
- 0.10
- P/E (TTM)
- -10.1
- EPS (TTM)
- -$0.91
Volume 0.88M
Average 1.07M
IMMX Weighted Avg Shares
Average number of basic shares outstanding during the period, used to calculate basic EPS.
Immix Biopharma, Inc.NASDAQ: IMMX
Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares growth accelerates
Q1 FY2026 weighted avg shares of 38.29M shares rose 28.9% year over year, ahead of the +19.9% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +33.4% a year.
Context
- Weighted avg shares increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +28.9% holds above the trailing-twelve-month pace of +19.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares history
Shares · from the income statement
- Latest · FY2025
- 32.97M USD
- Year-over-year change
- +16.5%
- 4-year CAGR
- +73.1%
| Period | Period end | Weighted Avg Shares | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 32.97M | +16.5% |
| FY2024 | 2024-12-31 | 28.29M | +63.1% |
| FY2023 | 2023-12-31 | 17.34M | +24.9% |
| FY2022 | 2022-12-31 | 13.89M | +278.1% |
| FY2021 | 2021-12-31 | 3.67M | — |
Weighted Avg Shares vs competitors
How IMMX compares with its peers on the latest reported figures
- IMMX's LTM Mar 2026 weighted avg shares of 34.62M shares is the 10th highest of the 11 companies compared; the peer median is 72.27M shares.
- Its year-over-year change of +19.9% is the 7th highest of 11, against a peer median of +20.7%.
- Over three fiscal years its annual growth of +33.4% compares with a peer median of +17.2%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 160.38M | +90.3% | +28.0% | |
| FY2025 | 145.58M | +21.3% | +19.1% | |
| LTM Jun 2026 | 116.35M | +20.1% | +14.3% | |
| LTM Aug 2026 | 106.95M | +29.6% | +21.3% | |
| LTM Sep 2026 | 72.36M | +9.0% | +12.4% | |
NBPNovaBridge Biosciences | LTM Sep 2025 | 72.17M | -12.1% | -20.4% |
| FY2025 | 69.53M | +10.3% | +53.9% | |
| LTM Mar 2026 | 67.15M | +30.5% | +15.3% | |
| LTM Mar 2026 | 63.24M | +0.8% | +0.9% | |
| LTM Mar 2026 | 34.62M | +19.9% | +33.4% | |
| LTM Mar 2026 | 19.58M | +98.7% | +69.8% | |
| Peer median (excluding IMMX) | 72.27M | +20.7% | +17.2% | |
Competitors are the stored peer set for IMMX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 364.5K |
| Gross Profit | 0 | 0 | 0 | 0 | (364.5K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 126.53K | 4.2M | 8.74M | 11.29M | 16.26M |
| Selling, General & Admin | 1.23M | 4.02M | 7.41M | 11.38M | 13.7M |
| Operating Expenses | 1.35M | 8.22M | 16.14M | 22.67M | 26.85M |
| Depreciation & Amortization | 2.47K | 2.14K | 5.47K | 115.39K | 364.5K |
| EBITDA | (24.2M) | (8.22M) | (15.56M) | (21.54M) | (29.04M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (1.35M) | (8.22M) | (16.14M) | (22.67M) | (27.21M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 572.01K | 1.02M | 555.53K |
| Interest Expense | 179.85K | 497 | 0 | 0 | 0 |
| Other Income / Expenses | (23.03M) | (497) | 572.01K | 1.02M | (2.19M) |
| Income Before Tax | (24.38M) | (8.22M) | (15.57M) | (21.66M) | (29.4M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 6.01K | 10.27K | 26.42K | 41.04K | 37.72K |
| Net Income | (24.38M) | (8.23M) | (15.43M) | (21.61M) | (29.44M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (6.64) | (0.59) | (0.89) | (0.76) | (0.89) |
| EPS (Diluted) | (6.64) | (0.59) | (0.89) | (0.76) | (0.89) |
| Weighted Avg Shares | 3.67M | 13.89M | 17.34M | 28.29M | 32.97M |
| Weighted Avg Shares (Diluted) | 3.67M | 13.89M | 17.34M | 28.29M | 32.97M |
Immix Biopharma, Inc.
NASDAQ:IMMX
Intrinsic Alpha fair value
Locked
Current Price
$7.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.